✦ LIBER ✦

P-551 A phase II randomized trial of weekly versus. 3-weekly docetaxel as second line treatment for non-small cell lung cancer

✍ Scribed by Tsai, Chun-Ming; Chiu, Chao-Hua; Wang, Gwo-Shu; Su, Wei-Juin; Chen, Yuh-Min; Perng, Reury-Perng

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of weekly docetaxel (D) i

✍ Lilenbaum, R; Schwartz, M; Siegel, L; Belette, F; Blaustein, A; Wittlin, F; Cisn 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Weekly docetaxel as second line chemothe

✍ Emilio Bria; Federica Cuppone; Mariangela Ciccarese; Cecilia Nisticò; Francesco 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 208 KB

Randomized phase II trial comparing tras

✍ Krug, L.M; Miller, V.A; Crapanzano, J.P; Zakowski, M.F; Ng, K.K; Heelan, R.T; Ro 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 118 KB

Weekly docetaxel vs. docetaxel-based com

✍ Gebbia, Vittorio; Gridelli, Cesare; Verusio, Claudio; Frontini, Luciano; Aitini, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 334 KB

P-576 Phase II trial of weekly topotecan

✍ Greco, F. Anthony; Burris, Howard A.; Yardley, Denise Aysel; Hainsworth, John Da 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 172 KB

Phase II trial of weekly docetaxel in se

✍ Rogerio C. Lilenbaum; Michael A. Schwartz; Leonard Seigel; Francisco Belette; Ar 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

The authors thank Jim Herndon, Ph.D., for the statistical analysis and Ana Maria Gonzalez-Angulo, M.D., for article review and preparation.